Scarica l'app Stockscreener
147.86
0.85%
-1.27
Pre-mercato:
146.00
-1.86
-1.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$149.13
Aprire:
$148.82
Volume 24 ore:
2.45M
Relative Volume:
1.50
Capitalizzazione di mercato:
$21.68B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
14.15
EPS:
10.453
Flusso di cassa netto:
$1.85B
1 W Prestazione:
+0.09%
1M Prestazione:
+6.74%
6M Prestazione:
+23.04%
1 anno Prestazione:
-19.41%
Intervallo 1D:
$147.54
$149.91
Intervallo di 1 settimana:
$147.54
$151.92
Portata 52W:
$110.03
$185.00
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
147.86 | 21.86B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
813.53 | 735.18B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.60 | 450.37B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.14 | 401.96B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
121.80 | 238.94B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.58 | 217.38B | 63.43B | 16.42B | 14.72B | 6.4861 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Iniziato | Jefferies | Buy |
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Analyzing Biogen Inc. with multi timeframe charts2025 Top Gainers & Daily Volume Surge Signals - newser.com
Biogen (BIIB): Reassessing Valuation After Recent Share Price Momentum - simplywall.st
United States Biotechnology Market 2025: Industry - openPR.com
Why Biogen Inc. (IDP) stock stays on top picksWeekly Investment Summary & Safe Capital Growth Tips - newser.com
PEGylated Proteins Market See Incredible Growth 2025-2032 | Biogen Inc, Pfizer Inc, and UCB S.A. - openPR.com
Is Biogen Inc. stock a safe buy before earnings2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com
United States Biosimilars Market is expected to reach US$ 171.79 - openPR.com
Nisa Investment Advisors LLC Has $6.39 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Brighton Jones LLC Purchases New Stake in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. stock a top momentum playJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data - BioSpace
Will Biogen Inc. (IDP) stock benefit from commodity supercycleJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Volatility clustering patterns for Biogen Inc.Earnings Risk Summary & Fast Entry High Yield Tips - newser.com
Will Biogen Inc. (IDP) stock benefit from sector leadershipJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com
Sumitomo Mitsui Trust Group Inc. Decreases Stake in Biogen Inc. $BIIB - MarketBeat
Key metrics from Biogen Inc.’s quarterly dataPortfolio Risk Summary & Technical Pattern Alert System - newser.com
Biogen Inc.’s volatility index tracking explainedMarket Performance Report & Verified Short-Term Plans - newser.com
Historical volatility pattern of Biogen Inc. visualizedLong Setup & Weekly Top Gainers Alerts - newser.com
United States Inflammatory Bowel Disease Market is expected - openPR.com
Will Biogen Inc. stock gain from strong economyJuly 2025 Earnings & Fast Gaining Stock Reports - Fundação Cultural do Pará
Institutional scanner results for Biogen Inc.July 2025 Rallies & Technical Analysis for Trade Confirmation - newser.com
Is Biogen Inc. (IDP) stock a buy on weaknessJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com
How to escape a deep drawdown in Biogen Inc.Weekly Loss Report & Daily Chart Pattern Signal Reports - newser.com
Biogen’s Felzartamab Trial: A New Hope for Kidney Transplant Patients - TipRanks
Biogen’s PMN Study: A Potential Game-Changer for Kidney Disease Treatment? - TipRanks
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment? - TipRanks
Biogen’s Litifilimab Study: A Promising Step for Lupus Treatment - TipRanks
Biogen’s New Study on Felzartamab: A Potential Game-Changer for Kidney Transplant Patients - TipRanks
Biogen’s Study on Diroximel Fumarate: A Closer Look at Pregnancy Outcomes - TipRanks
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks
Biogen’s Litifilimab Study: A Potential Game-Changer in Lupus Treatment? - TipRanks
Biogen’s Nusinersen Study: Exploring Pregnancy Outcomes in SMA Patients - TipRanks
Biogen’s Innovative Approach in SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks
Biogen’s Innovative Approach to SMA Treatment: A Study Update - TipRanks
Biogen’s New Study on Omaveloxolone: A Potential Game-Changer for Friedreich’s Ataxia - TipRanks
Biogen’s BIIB142 Study: A New Chapter in Drug Safety Evaluation - TipRanks
Biogen and Denali’s New Study on LRRK2-Associated Parkinson’s Disease: What Investors Need to Know - TipRanks
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights - TipRanks
Biogen, Inc. Experiences Valuation Adjustment Amidst Market Performance Challenges - Markets Mojo
Biogen’s Pregnancy Exposure Study: Implications for MS Treatment Market - TipRanks
Biogen’s Zuranolone Study: A Potential Game-Changer for Postpartum Depression Treatment - TipRanks
Biogen’s Omaveloxolone Study: Assessing Safety During Pregnancy and Lactation - TipRanks
Biogen’s New MS Study: A Potential Game-Changer for Investors? - TipRanks
Biogen’s Omaveloxolone Study: A Closer Look at Long-Term Safety for Friedreich’s Ataxia - TipRanks
Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow - Morningstar
Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer’s Disease - Cantech Letter
Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer's Disease - Newswire Canada
AustralianSuper Pty Ltd Has $92.86 Million Stake in Biogen Inc. $BIIB - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat
Using portfolio simulators with Biogen Inc. includedMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
0.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):